Financial analysts tracking Sana Biotechnology (NASDAQ: SANA) maintain a strong consensus bullish outlook, with average price targets projecting significant upside potential. Wall Street forecasts place the average twelve-month stock price target around eight dollars and forty-three cents, with predictions ranging from a conservative low of approximately six dollars up to a high of twelve dollars per share. These optimistic targets reflect strong institutional confidence in the company's innovative gene therapy and engineered cell platforms, despite ongoing early-stage clinical trial expenditures.